Lord Abbett Health Care Fund Class R5 LHCTX

Medalist Rating as of | See Lord Abbett Investment Hub
  • NAV / 1-Day Return 23.68  /  +0.17 %
  • Total Assets 8.6M
  • Adj. Expense Ratio
    0.780%
  • Expense Ratio 0.780%
  • Distribution Fee Level Below Average
  • Share Class Type Retirement, Large
  • Category Health
  • Investment Style Mid Growth
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 0.36%
  • Turnover 91%

USD | NAV as of Jul 16, 2026 | 1-Day Return as of Jul 16, 2026, 12:11 AM GMT+0

Morningstar’s Analysis LHCTX

Will LHCTX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Lord Abbett Health Care R5 holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings LHCTX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 43.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

10.78 856,375
Healthcare

AstraZeneca PLC

4.75 377,133
Healthcare

Gilead Sciences Inc

4.48 355,836
Healthcare

Guardant Health Inc

4.01 318,908
Healthcare

UnitedHealth Group Inc

3.91 310,713
Healthcare

Natera Inc

3.24 257,099
Healthcare

Johnson & Johnson

3.20 254,398
Healthcare

CVS Health Corp

3.13 248,739
Healthcare

argenx SE

2.79 222,024
Healthcare

Galderma Group AG Registered Shares

2.75 218,283
Healthcare

Sponsor Center